Cantourage Group SE Stock: price and directors' dealings · Germany · BaFin

About Cantourage Group SE

Cantourage Group SE is a German company focused on medical cannabis, listed on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany under the ticker HIGH.DE. Founded in 2019 and headquartered in Berlin, the company has built its business around a European medical-cannabis platform model spanning sourcing, processing, commercialization, and distribution of flowers and related products for patients and healthcare professionals. Its strategy centers on providing selected strains and products that are designed to meet the regulatory standards of medical markets across Europe. ([stockanalysis.com](https://stockanalysis.com/quote/etr/HIGH/company/?utm_source=openai)) Operationally, Cantourage is primarily exposed to the medical-cannabis segment, with a strong historical emphasis on Germany while expanding into other European markets, notably the UK and Poland. The company also highlights processing and supply-chain capabilities in Germany and Portugal, pointing to a cross-border operating footprint. Management has positioned the group around product diversification and internationalization to reduce reliance on a single market and capture growth across Europe’s evolving medical-cannabis frameworks. ([cantourage.com](https://www.cantourage.com/en/blog-posts/cantourage-achieves-new-revenue-record-eur-11-1-million-in-april-2025?utm_source=openai)) Cantourage is among the more visible listed players in European medical cannabis. Its value proposition combines regulatory expertise, a product portfolio, access to prescription channels, and the ability to serve a growing patient base. The competitive backdrop remains demanding, however, especially in Germany, where price pressure in medical cannabis flowers can weigh on margins. The company has stated that it is shifting its portfolio toward higher-margin premium products, which underlines the importance of mix and pricing in its financial profile. ([eqs-news.com](https://www.eqs-news.com/news/corporate/cantourage-group-se-publishes-preliminary-figures-for-2025-revenue-rises-to-eur-92-8-million/46257867-d503-47fd-ac34-736f7f5ff130_en?utm_source=openai)) Recent milestones include preliminary 2025 figures showing revenue of EUR 92.8 million, with management emphasizing continued growth and the rising contribution of international markets. Cantourage also reported a record monthly revenue in April 2025 and strong trading momentum in Q1 2025. These updates reinforce the company’s rapid growth trajectory, while also highlighting the regulatory sensitivity of the German market. For investors, Cantourage is a niche healthcare exposure with meaningful upside potential, but one that remains closely tied to legal, pricing, and market-structure developments in medical cannabis. ([eqs-news.com](https://www.eqs-news.com/news/corporate/cantourage-group-se-publishes-preliminary-figures-for-2025-revenue-rises-to-eur-92-8-million/46257867-d503-47fd-ac34-736f7f5ff130_en?utm_source=openai))